{
    "clinical_study": {
        "@rank": "20049", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants age 12 to 17 will be enrolled.\nPart A: No participants will be enrolled in Part A, as PK data is currently available for this age group.\nPart B: Participants will receive Elvitegravir (EVG) plus a background regimen that includes a PI/r for up to 48 weeks."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants age 6 to 11 will be enrolled in Part A first. After pharmacokinetic (PK) assessment of Part A, participants will be enrolled in Part B.\nPart A: Participants will receive Elvitegravir (EVG) plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL who complete Part A may then choose to continue in Part B.\nPart B: Following PK assessment, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, multicohort, two-part study to confirm the dose and\n      evaluate the safety and tolerability of ritonavir-boosted elvitegravir (EVG/r) in HIV-1\n      infected, treatment-experienced subjects aged 4 weeks to less than 18 years of age. The dose\n      of EVG will be determined by intensive pharmacokinetic sampling at Day 10. The safety and\n      antiviral activity of EVG will also be evaluated."
        }, 
        "brief_title": "Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acquired Immune Deficiency Syndrome (AIDS)", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects must meet all of the following inclusion criteria to be eligible for\n        participation in this study. Subjects with screening results that do not meet eligibility\n        criteria will not be allowed to rescreen.\n\n          -  HIV-1 infected male and female subjects 4 weeks (gestational age of at least 44\n             weeks) to less than 18 years of age at Baseline.\n\n          -  Subjects are able to provide written assent if they have the ability to read and\n             write.\n\n          -  Parent or legal guardian able to provide written informed consent prior to any\n             screening evaluations and willing to comply with study requirements.\n\n          -  Body weight at screening greater than 5kg, 10.6kg, or 15kg dependent upon age cohort\n\n          -  Adequate renal function\n\n          -  Adequate hematologic function\n\n          -  Hepatic transaminases (AST and ALT) less than or equal to 5 x upper     limit of\n             normal (ULN)\n\n          -  Total bilirubin less than or equal to 1.5 mg/dL, or normal direct bilirubin\n\n          -  Negative serum pregnancy test\n\n          -  Subjects with evidence of suppressed viremia\n\n          -  Subjects failing a current antiretroviral regimen at study entry\n\n          -  Male and female subjects of childbearing potential must agree to utilize highly\n             effective contraception methods while on study treatment or agree to abstain from\n             heterosexual intercourse throughout the study period and for 30 days following the\n             last dose of study drug\n\n          -  Must be willing and able to comply with all study requirements.\n\n        Exclusion Criteria:\n\n        Subjects who meet any of the following exclusion criteria are not to be enrolled in this\n        study.\n\n          -  Subjects with CD4+ cell counts at Screening of less than 50, 75, or 200 cells/mm3\n             dependent on age cohort\n\n          -  An AIDS defining condition with onset within 30 days prior to screening\n\n          -  Life expectancy of less than 1 year\n\n          -  For subjects with HIV-1 RNA greater than 1,000 copies/mL at screening, prior\n             treatment of any duration with an integrase strand transfer inhibitor.\n\n          -  An ongoing serious infection requiring systemic antibiotic therapy at the time of\n             screening.\n\n          -  Evidence of active pulmonary or extra-pulmonary tuberculosis disease\n\n          -  Anticipated requirement for rifamycin treatment while participating in the study.\n\n          -  Have any serious or active medical or psychiatric illness which, in the opinion of\n             the Investigator, would interfere with subject treatment, assessment, or compliance\n             with the protocol.\n\n          -  Subjects experiencing decompensated cirrhosis\n\n          -  A history of or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal\n             cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.\n\n          -  Pregnant or lactating subjects.\n\n          -  Current alcohol or substance abuse judged by the Investigator to potentially\n             interfere with subject compliance.\n\n          -  Have history of significant drug sensitivity or drug allergy.\n\n          -  Known hypersensitivity to the study drug, the metabolites, or formulation excipients.\n\n          -  Have previously participated in an investigational trial involving administration of\n             any investigational agent within 30 days prior to the study dosing.\n\n          -  Participation in any other clinical trial without prior approval from sponsor is\n             prohibited while participating in this trial.\n\n          -  Subjects receiving ongoing therapy with any medication that is not to be taken with\n             EVG or a component of the BR, including drugs not to be used with ritonavir"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923311", 
            "org_study_id": "GS-US-183-0160", 
            "secondary_id": "2013-001969-16"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "EVG (50 mg, 85 mg, or 150 mg tablets or 5 mg/mL powder for oral suspension) administered orally once daily with food", 
                "intervention_name": "Elvitegravir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2"
                ], 
                "description": "Participants will receive a background regimen consisting of ritonavir (RTV; /r)-boosted protease inhibitor (PI/r). The PI/r contained in the background regimen must be one of the following: lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For subjects < 2 months old, only lopinavir/r is allow. Use of additional antiretrovirals in background therapy may be allowed.\nParticipants with HIV-1 RNA < 50 copies/mL will receive their current PI/r as background regimen\nParticipants with HIV-1 RNA > 1,000 copies/mL will receive a newly constructed PI/r background regimen  selected by the investigator.", 
                "intervention_name": "RTV-boosted PI", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Protease Inhibitors", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pediatrics", 
            "Adolescents", 
            "HIV", 
            "HIV-1", 
            "Treatment-experienced"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Marilyn Crain, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90027"
                    }, 
                    "name": "Jeffrey Goodman Clinic Los Angeles Gay and Lesbian Center"
                }, 
                "investigator": {
                    "last_name": "Church Joseph, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Denver"
                }, 
                "investigator": {
                    "last_name": "Elizabeth McFarland, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32209"
                    }, 
                    "name": "University of Florida, Jacksonville"
                }, 
                "investigator": {
                    "last_name": "Mobeen H. Rathore, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampla", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "University of South Florida College of Medicine"
                }, 
                "investigator": {
                    "last_name": "Jorge Lujan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Emory-Children's Center - Ponce Family and Youth Clinic"
                }, 
                "investigator": {
                    "last_name": "Rana Chakraborty, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ellen Cooper, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016-6481"
                    }, 
                    "name": "NYU School of Medicine Pediatrics"
                }, 
                "investigator": {
                    "last_name": "William Borkowsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical University"
                }, 
                "investigator": {
                    "last_name": "Leonard Weiner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Coleen Cunningham, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38105"
                    }, 
                    "name": "St. Jude Children's Research Hospital"
                }, 
                "investigator": {
                    "last_name": "Aditya Gaur, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Health Science Center at Houston"
                }, 
                "investigator": {
                    "last_name": "Gloria Heresi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Charite-Universitaetsmedizin Berlin-Klinik f\u00fcr P\u00e4diatrie mit Schwerpunkt Pneumologie und Immunologie"
                }, 
                "investigator": {
                    "last_name": "Cornelia Feiterna-Sperling", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Johann Wolfgang Goethe-University Hospital"
                }, 
                "investigator": {
                    "last_name": "Christoph Koenigs", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20122"
                    }, 
                    "name": "UOSD Pediatria ad Alta Intensit\u00e0 di Cura"
                }, 
                "investigator": {
                    "last_name": "Susanna Esposito", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "zip": "27100"
                    }, 
                    "name": "Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo"
                }, 
                "investigator": {
                    "last_name": "Lorenzo Minoli", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7646"
                    }, 
                    "name": "Be Part Yoluntu Centre"
                }, 
                "investigator": {
                    "last_name": "Lize Hellstrom", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "South Africa", 
                        "zip": "3000"
                    }, 
                    "name": "Mpati Medical Centre"
                }, 
                "investigator": {
                    "last_name": "Jan Fourie", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4001"
                    }, 
                    "name": "Gulam Latiff Private Practice"
                }, 
                "investigator": {
                    "last_name": "Gulam Latiff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2112"
                    }, 
                    "name": "Rahima Moosa Mother and Child Hopsital"
                }, 
                "investigator": {
                    "last_name": "Renate Strehlau", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Soweto", 
                        "country": "South Africa", 
                        "zip": "2013"
                    }, 
                    "name": "Perinatal HIV Research Unit"
                }, 
                "investigator": {
                    "last_name": "Avy Violari", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "8950"
                    }, 
                    "name": "Hospital Sant Joan De Deu"
                }, 
                "investigator": {
                    "last_name": "Claudia Fortuny Guasch", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Getafe Madrid", 
                        "country": "Spain", 
                        "zip": "28095"
                    }, 
                    "name": "Hospital Universitario De Getafe"
                }, 
                "investigator": {
                    "last_name": "Jos\u00e9 Tom\u00e1s Ramos Amador", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Maria Isabel Gonzalez-Tome", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10330"
                    }, 
                    "name": "Thai Red Cross AIDS Research Centre (HIV-NAT)"
                }, 
                "investigator": {
                    "last_name": "Wasana Prasitsuebsai", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Siriraj Hospital"
                }, 
                "investigator": {
                    "last_name": "Kulkanya Chokephaibulkit", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Khon Kaen", 
                        "country": "Thailand", 
                        "zip": "40002"
                    }, 
                    "name": "Srinagarind Hospital"
                }, 
                "investigator": {
                    "last_name": "Pope Kosalaraksa", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kampala", 
                        "country": "Uganda"
                    }, 
                    "name": "Joint Clinical Research Centre"
                }, 
                "investigator": {
                    "last_name": "Victor Musiime", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Italy", 
                "South Africa", 
                "Spain", 
                "Thailand", 
                "Uganda"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG)Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects", 
        "overall_contact": {
            "email": "skanda.goudar@gilead.com", 
            "last_name": "Skanda Goudar", 
            "phone": "650-522-4274"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Sean Bennett, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)\nCmax is defined as the maximum concentration of drug", 
                "measure": "Plasma pharmacokinetics (PK) parameters of EVG as measured by AUCtau and Cmax", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "The incidence of treatment-emergent adverse events and laboratory abnormalities will be summarized.", 
                "measure": "Incidence of treatment-emergent adverse events and laboratory abnormalities", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 48"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Ctau is defined as the observed drug concentration at the end of the dosing interval\nCL/F is the apparent oral clearance following administration of the drug\nVz/F is the apparent volume of distribution of the drug", 
                "measure": "PK parameters of EVG as measured by Ctau, CL/F, and Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "measure": "Percentage of participants with plasma HIV-1 RNA < 50 and < 400 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "Change from baseline in plasma log10 HIV-1 RNA", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 24 and 48"
            }, 
            {
                "description": "Tanner Stages at Weeks 24 and 48 will be summarized by baseline Tanner Stage using frequency and percentage. Age of first menses will be summarized descriptively.", 
                "measure": "Tanner Stages at Weeks 24 and 48, and age of first menses", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48 and age of first menses"
            }, 
            {
                "measure": "Palatability of oral suspension formulation of EVG in appropriate age group", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 48"
            }, 
            {
                "description": "Treatment adherence will be assessed at all post-baseline visits.", 
                "measure": "Adherence to EVG", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 48"
            }, 
            {
                "measure": "The change from baseline in CD4+ cell count (cells/\u03bcL)", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }, 
            {
                "measure": "The change from baseline in CD4 percentage", 
                "safety_issue": "No", 
                "time_frame": "Weeks 24 and 48"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}